Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

16

Exagen Inc. Expands Coverage with Alivio Health

Partnership to provide more accurate diagnostic testing with AVISE® CTD and AVISE® Lupus SAN...

11

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly...

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

Studying the delivery of SD-101 via pressure-enabled drug delivery in adults with hepatocellular carcinoma...

5

electroCore Announces Record First Quarter 2022 Financial Results

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially...

5

ATEC Reports First Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

Revenue growth of 61%, including organic revenue growth of 39% EOS imaging revenue of...

1

Exagen Announces Five-Week Campaign for Lupus Awareness Month

Weekly themes to focus on diagnosis, advocacy, community, research, and motivation SAN DIEGO, May 01,...

21

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

Evaluation results indicate nVNS therapy may potentially improve the course of patients’ COVID-19 symptoms...

19

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

If initial findings are confirmed, program calls for field-ready gammaCore™ nVNS devices in 2H-2023 ROCKAWAY,...

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

Immunotherapeutic collaboration will advance efforts to develop new treatment options for patients with liver...

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021...

5

ATEC to Host Investor Day on May 25, 2022

In-person and virtual event will take place 9am – 12pm PT CARLSBAD, Calif.–(BUSINESS WIRE)–...

Recent developments

News

May

16

Exagen Inc. Expands Coverage with Alivio Health

May

11

Exagen Inc. Reports First Quarter 2022 Results

May

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

May

10

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial

May

5

electroCore Announces Record First Quarter 2022 Financial Results

May

5

ATEC Reports First Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

May

1

Exagen Announces Five-Week Campaign for Lupus Awareness Month

April

21

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

April

19

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program

April

12

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

April

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

April

5

ATEC to Host Investor Day on May 25, 2022